^
    Back
    Association details:
    Biomarker:IL2RA elevation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:PD1 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Invest New Drugs
    Title:

    Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients

    Published date:
    04/14/2023
    Excerpt:
    We evaluated the association between serum sIL-2R levels and the efficacy of anti-programmed cell death 1/ programmed death-ligand 1 (anti-PD-1/PD-L1) antibody combined with chemotherapy in non-small cell lung cancer (NSCLC) patients….Multivariate Cox regression analysis showed that high sIL-2R was significantly associated with shorter PFS and OS. SIL-2R may be a biomarker for the poor efficacy of anti-PD-1/PD-L1 antibody combined with chemotherapy.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1007/s10637-023-01358-3